ALECTOR INC. - COMMON STOCK

Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation

29 Jul 2021 10:10:00 By Nasdaq GlobeNewswire

Alector to Present New Data from Frontotemporal Dementia and Alzheimer’s Disease Programs at the 2021 Alzheimer’s Association International Conference

21 Jul 2021 16:35:14 By Nasdaq GlobeNewswire

Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases

02 Jul 2021 07:38:44 By Nasdaq GlobeNewswire

Alector to Present at Upcoming Virtual Healthcare Conferences

03 Jun 2021 16:05:00 By Nasdaq GlobeNewswire

Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021

26 May 2021 16:05:00 By Nasdaq GlobeNewswire

Alector to Present at the BofA Securities 2021 Virtual Health Care Conference

06 May 2021 16:05:01 By Nasdaq GlobeNewswire

Alector Reports 2021 First Quarter Financial Results and Provides Business Update

05 May 2021 16:05:01 By Nasdaq GlobeNewswire

Alector to Present at Stifel’s 3rd Annual CNS Day

25 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Alector to Present at the Barclays Global Healthcare Conference

04 Mar 2021 16:05:01 By Nasdaq GlobeNewswire

Alector Reports 2020 Fourth Quarter and Full Year Financial Results and Provides Business Update

25 Feb 2021 16:05:00 By Nasdaq GlobeNewswire

Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease

25 Jan 2021 08:30:00 By Nasdaq GlobeNewswire

Alector Announces Departure of Chief Business Officer

20 Jan 2021 16:15:00 By Nasdaq GlobeNewswire

Alector Provides 2021 Corporate Portfolio Update

07 Jan 2021 16:05:00 By Nasdaq GlobeNewswire